Intended laboratory context
Illustrative applications
- Analytical method development
- Identity and retention-time comparison
- Qualified receptor-assay research
- Non-clinical laboratory investigation
Lyophilized Peptides
Retatrutide Research Reference
LY3437943
A synthetic, lipidated peptide research reference characterized in the literature as an agonist of human GCGR, GLP-1R and GIPR.
CatalogGR-PW
ManufacturerRemetide
PurityProposed ≥99% by RP-HPLC; lot result controls
PackResearch pack · supplied amount shown on product record
Price range: $75.00 through $449.00 Current catalog price; lot availability controls fulfillment.
AvailabilityIn stock
For laboratory research use only. Not for human or veterinary use.
Retatrutide Research Reference$75.00 – $449.00Price range: $75.00 through $449.00
01Lot documentationCOA and analytical-record model
02Defined specificationMethod and result remain lot specific
03Tracked fulfillmentShipping method and lot allocation confirmed at order review
04Responsible useNon-clinical laboratory context
Technical information
Chemical & material record
Presented in a scientific-catalog format so the material can be evaluated by identity, form and documentation before purchase.
- Identity
- Retatrutide research reference
- Synonyms
- LY3437943
- CAS number
- 2381089-83-2
- Molecular formula
- C221H342N46O68
- Formula weight
- 4,731.3 Da
- Sequence / identity note
- 39-residue modified peptide; sequence controlled in the technical record
- Manufacturer
- Remetide
- Manufacturing role
- Custom peptide synthesis and manufacture
- Form
- Lyophilized, non-sterile research material
- Purity specification
- Proposed ≥99% by RP-HPLC; lot result controls
- Storage
- -20°C, dry and protected from light; follow lot documentation
- Pack size
- Research pack · supplied amount shown on product record
- Catalog number
- GR-PW
Product description
Published context, clearly separated from lot claims.
A technical catalog should make the chemical record, relevant experimental literature and product-specific documentation independently reviewable.
Retatrutide (LY3437943) is a 39-residue modified peptide studied as a triple agonist of the glucagon receptor (GCGR), glucagon-like peptide-1 receptor (GLP-1R) and glucose-dependent insulinotropic polypeptide receptor (GIPR). Published receptor studies used human receptor-expressing HEK293 systems to characterize cAMP signaling.
In those cellular assays, reported EC50 values were 5.79 nM at GCGR, 0.775 nM at GLP-1R and 0.0643 nM at GIPR. Separate non-clinical mouse studies evaluated glucose tolerance, gastric emptying and metabolic endpoints. These observations describe the cited studies, not a specification or expected result for this lot.
Selected published findings
- Induced cAMP accumulation in HEK293 cells expressing human GCGR, GLP-1R or GIPR.
- Was evaluated in mouse models for glucose-tolerance, gastric-emptying and diet-induced-obesity endpoints.
References and product citations 2
- Coskun, T., Urva, S., Roell, W.C., et al. LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist: from discovery to clinical proof of concept. Cell Metabolism 34(9), 1234–1247 (2022).
- Urva, S., O’Farrell, L., Du, Y., et al. The novel GIP, GLP-1 and glucagon receptor agonist retatrutide delays gastric emptying. Diabetes, Obesity and Metabolism 25(9), 2784–2788 (2023).
Literature interpretation: This summary describes published experimental literature and is not a lot specification, clinical claim, use instruction or representation that the supplied research material will reproduce a published result. This record intentionally excludes dosing, administration, clinical outcomes, patient eligibility and therapeutic comparisons.
Proposed package
Documentation
- PDFIllustrative Certificate of AnalysisSample
- PDFAnalytical summarySample
- PDFMaterial handling statementSample
- PDFProject-specific specificationSample
Not offered for clinical, diagnostic, compounding, therapeutic, human or veterinary use. Current labeling, specification and lot documentation control.
Need a current record?
Documentation before decision-making.
Reference GR-PW and the applicable lot when contacting technical support. Published files support evaluation but do not replace the approved lot COA or material specification.
View documentation model